Pharma major Dr Reddy’s Laboratories Ltd has been sued by Bristol-Myers Squibb Company for patent infringement of cancer drug Ixempra.
The US-based Bristol-Myers filed the case in the district court of New Jersey after the Hyderabad-based company informed it about the Abbreviated New Drug Application for the product as per the regulation of the US Food and Drug Administration.
In the petition, Bristol-Myers claimed that it had developed and manufactures Ixempra, indicated for both mono-therapy and combination therapy for breast cancer treatment. It has further claimed that DRL has now sought approval to market a generic version of Ixempra for at least one of the uses.
The US drug maker has sought damages or other relief if Dr Reddy’s engages in commercial manufacture and sale of the ANDA product that infringes the patents of its drug. When contacted, a functionary of Dr Reddy’s Laboratories termed the matter as ‘routine’ and added that the company’s intellectual properties team would work on such issues.